JMP Securities Downgrades Vitae Pharmaceuticals (VTAE) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Buy Vitae Pharmaceuticals (VTAE) on Weakness, Piper Jaffray Says
June 30, 2015 7:07 AM EDTPiper Jaffray analyst Edward Tenthoff lowered his price target on Vitae Pharmaceuticals (NASDAQ: VTAE) to $20.50 (from $23.00) after its Boehringer Ingelheim partnered diabetes drug VTP-34072 failed in combination with metformin in a Phase II trial. However, the firm is maintaining an Overweight... More
Wedbush Maintains Bullish View on Vitae Pharma (VTAE) Even as VTP-34072 for Diabetes Essentially Shelved
June 29, 2015 12:42 PM EDTWedbush analyst Liana Moussatos trimmed her price target on Vitae Pharmaceuticals (NASDAQ: VTAE) to $20.00 (from $21.00) after VTP-34072 for diabetes is essentially shelved. However, the firm maintained an Outperform rating.
"Even though the program is not formally discontinued and data from the... More
Vitae Pharmaceuticals (VTAE) Announces BI187004/VTP-34072 Phase 2 Missed Primary Efficacy Endpoint
June 29, 2015 6:33 AM EDTVitae Pharmaceuticals (NASDAQ: VTAE) announced top-line clinical efficacy results from the metformin arm of an ongoing Phase 2 proof-of-concept clinical trial of BI187004/VTP-34072 in the treatment of overweight type 2 diabetic patients. BI187004/VTP-34072 is a potential first-in-class 11-hydroxysteroid dehydrogenase type 1 (11 HSD1) inhibitor that was discovered by... More
